• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Successful BioPharma Startups Focus on the Science

    Danielle Adams
    Apr. 15, 2019 02:44PM PST
    Biotech Investing
    OTCQB:BCTXF

    BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF) was featured in an article by BioPharm International on process development in biopharma startups.

    BioPharm International has recently published an article covering the process development in biopharma startups as they work to bring a commercially viable product to market. According to the article, most biopharma startups focus their efforts on attracting skilled talent and raising capital for their research. Process development, however, becomes an afterthought which can affect that startup’s ability to turn its concept into a commercially-viable product. Unknown companies also have trouble securing equipment and material vendors which can hinder that company’s ability to demonstrate credibility.

    For companies like BriaCell Therapeutics Corp. (TSX:BCT, OTC:BCTXF), an immuno-oncology company developing targetted immunotherapies for multiple cancer indications, process development can mean several different things. For BriaCell CEO Bill Williams, there are three aspects involved with process development: process development in the production of its novel therapeutics, the design and implementation of clinical trials and the selection of new drug targets.

    Process development can also be developed in-house or outsourced. BriaCell oversees the development of its therapies and has worked with clinical research organizations (CRO) with experience in developing cellular therapies or in collaboration with regulatory experts. For its clinical trials, BriaCell designs the studies and has a CRO conduct the experiment, which ensures patient recruitment and treatment remains with the CRO. New drug target selection and strategy design to develop effective drugs, however, is done entirely in-house.

    “It all falls into place based on who possesses the appropriate expertise and access to the corresponding resources,” said Williams.

    Click here to connect with BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF) for an Investor Presentation. 

    tsx:bctbriacell therapeutics corp.otcqb:bctxf
    The Conversation (0)

    Go Deeper

    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Biotech therapy capsule containing DNA strand surrounded by cells.

    Top 5 Canadian Biotech Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×